Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Treatment for Advanced or Recurrent Endometrial Cancer
Printer Friendly Page Treatment for Advanced or Recurrent  Endometrial Cancer

Treatment for Advanced or Recurrent Endometrial Cancer identifier:

Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer

Study Contact Information:

For additional information, please contact: 1-888-577-8839, Brian Slomovitz at [email protected] or [email protected]

This study is being run by GOG and ENGOT.

Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer

About the Study

This study is to test the safety and effectiveness of treatment with pembrolizumab, also known as Keytruda, compared to a combination of chemotherapy treatments in women with deficient mismatch repair () advanced or recurrent endometrial cancer who had not previously been treated with prior chemotherapy treatments. The study is being conducted to determine if pembrolizumab is better than the combined chemotherapy in terms of Progression Free Survival (PFS).

What the Study Entails

The study involves two group:

Group 1:

Participants receive pembrolizumab on Day 1 of each cycle, which lasts 6 weeks, for up to 18 cycles (about 2 years) injected into the vein.

Group 2:

Participants receive a combination chemotherapy of carboplatin and paclitaxel on Day 1 of each 3-week cycle for 6 cycles (about 4 months) injected into the vein.

Study Sites


  • Phoenix
    HonorHealth-USOR HonorHealth (Site 8000)
    Contact: Study Coordinator   (602) 406-7730


  • La Jolla
    Moores Cancer Center (Site 0037)
    Contact: Study Coordinator   (858) 822-6100
  • Riverside
    Kaiser Permanente Riverside Medical Center (Site 0045)
    Contact: Study Coordinator   (800) 398-3996


  • New Haven
    Smilow Cancer Center at Yale-New Haven (Site 0013)
    Contact: Study Coordinator   (203) 688-4242


  • Miami Beach
    Mount Sinai Cancer Center (Site 0018)
    Contact: Study Coordinator   (305) 674-2625
  • Sarasota 
    Sarasota Memorial Hospital (Site 0005)
    Contact: Study Coordinator (941) 917-2225


  • Atlanta
    Northside Hospital (Site 0017)
    Contact: Study Coordinator   (404) 851-8000
  • Newman
    Southeastern Regional Medical Center
    Contact: Study Coordinator   (770) 400-6000


  • Zion
    Midwestern Regional Medical Center, Inc (Site 0003)
    Contact: Study Coordinator (847) 731-1777


  • Indianapolis
    St. Vincent Hospital and Health Care Center, Inc (Site 0006)
    Contact: Study Coordinator   (317) 415-6740


  • Lexington
    Baptist Health Lexington (Site 0042)
    Contact: Study Coordinator   (502) 802-6829


  • Rockville
    Maryland Oncology Hematology (Site 8002)
    Contact: Study Coordinator   (301) 933-3216


  • Worcester
    University of Massachusetts Medical School - Division of Gynecologic Oncology (Site 0008)
    Contact: Study Coordinator   (508) 856-3216


  • Detroit
    Karmanos Cancer Institute (Site 0029)
    Contact: Study Coordinator   (800) 526-6266


  • Jackson
    St. Dominic’s Hospital (Site 0024)
    Contact: Study Coordinator   (601) 200-4974

New Jersey

  • Hackensack
    John Theurer Cancer Center at Hackensack University Medical Center (Site 0026)
    Contact: Study Coordinator   (551) 996-5855

New York

  • New York
    The Blavatnik Family - Chelsea Medical Center at Mount Sinai (Site 0023)
    Contact: Study Coordinator   (212) 694-6000
  • New York
    Laura and Isaac Perlmutter Cancer Center at NYU Langone (Site 0016)
    Contact: Study Coordinator   (212) 731-6455
  • New York
    Icahn School of Medicine at Mount Sinai (Site 0052)
    Contact: Study Coordinator   (212) 241-6500
  • New York
    Memorial Sloan Kettering Cancer Center (Site 0009)
    Contact: Study Coordinator   (646) 888-4224

North Carolina

  • Pinehurst
    FirstHealth CLinical Trials (Site 0050)
    Contact: Study Coordinator   (910) 715-2200

North Dakota

  • Bismark
    Sanford Medical Center (Site 0054)
    Contact: Study Coordinator   (605) 376-4905
  • Fargo
    Sanford Fargo Medical Center - Roger Maris Cancer Center (Site 0055)
    Contact: Study Coordinator   (605) 376-4905


  • Cincinnati
    University of Cincinnati Medical Center - University of Cincinnati Cancer Center (Site 0039)
    Contact: Study Coordinator   (513)584-7698
  • Columbus
    The James Cancer Hospital and Solove Research Institute at the Ohio State University Comprehensive Center
    Contact: Study Coordinator   (614) 293-3873


  • Portland
    Providence Portland Medical Center (Site 0031)
    Contact: Study Coordinator   (503) 215-2614


  • Philadelphia
    Sidney Kimmel Cancer Center - Jefferson Health (Site 0053)
    Contact: Study Coordinator   (215) 481-4000
  • Pittsburgh
    University of Pittsburgh Medical Center Magee-Womens Hospital (Site 0034)
    Contact: Study Coordinator   (412) 642-5411
  • Pittsburgh
    AHN West Penn Hospital (Site 0011)
    Contact: Study Coordinator   (412) 330-6151
  • Willow Grove
    Asplundh Cancer Pavilion (Site 0014)
    Contact: Study Coordinator   (215) 481-4000

South Dakota

  • Sioux Falls
    Sanford Cancer Center - Gynecologic Oncology (Site 0002)
    Contact: Study Coordinator   (605) 312-3250


  • Austin
    Texas Oncology - Austin-USOR Texas Oncology (Site 8003)
    Contact: Study Coordinator   (512) 421-4250
  • Dallas
    Texas Oncology - Dallas-USOR Texas Oncology (Site 8005)
    Contact: Study Coordinator   (214)370-1000
  • Tyler
    Texas Oncology - Tyler-USOR Texas Oncology (Site 8004)
    Contact: Study Coordinator   (903) 579-9800


  • Richmond
    VCU Health Adult Outpatient Pavillion (Site 0022)
    Contact: Study Coordinator   (804) 828-9080


This Study is Open To:

Women 18 years or older who:

  • have a diagnosis of III or IV or endometrial cancer that has recurred and that is confirmed
  • has received no prior for endometrial cancer except for radiation more than two weeks prior or hormonal therapy discontinued at least one week prior
  • is not pregnant or breastfeeding
  • has a negative pregnancy test within 24 hours of the study intervention
  • More inclusion criteria found on


This Study is Not Open To:

Patients who:

  • have uterine tumors 
  • are able to have surgery to remove all cancerous tissue or radiation intended to cure or delay the spread of cancer
  • have Microsatellite stable (MSS) or proficient mismatch repair (pMMR) endometrial cancer
  • have received prior chemotherapy, hormone therapy, , or
  • have received a major operation and have not completely recovered
  • have received a live vaccine within 30 days from the first dose of study intervention
  • have an active infection
  • have a known history of HIV (human immunodeficiency virus) 
  • have had a tissue or organ transplant
  • More exclusion criteria found on